H. James Ford

935 total citations
28 papers, 398 citations indexed

About

H. James Ford is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Physiology. According to data from OpenAlex, H. James Ford has authored 28 papers receiving a total of 398 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 10 papers in Cardiology and Cardiovascular Medicine and 6 papers in Physiology. Recurrent topics in H. James Ford's work include Pulmonary Hypertension Research and Treatments (20 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (8 papers) and Sarcoidosis and Beryllium Toxicity Research (5 papers). H. James Ford is often cited by papers focused on Pulmonary Hypertension Research and Treatments (20 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (8 papers) and Sarcoidosis and Beryllium Toxicity Research (5 papers). H. James Ford collaborates with scholars based in United States, Netherlands and Poland. H. James Ford's co-authors include R M Aris, Robert M. Aris, Wassim H. Fares, Marc A. Judson, Robert Roubey, Soon-Ho Kwon, Susan Burt, Kristin B. Highland, James F. Donohue and James F. Donohue and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, CHEST Journal and European Respiratory Journal.

In The Last Decade

H. James Ford

26 papers receiving 393 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H. James Ford United States 10 290 124 95 77 49 28 398
Takayuki Jujo Japan 13 423 1.5× 49 0.4× 256 2.7× 50 0.6× 83 1.7× 63 545
Koichiro Fukuda Japan 7 170 0.6× 46 0.4× 62 0.7× 32 0.4× 58 1.2× 12 300
Jerzy Piecuch Poland 12 93 0.3× 88 0.7× 54 0.6× 152 2.0× 56 1.1× 56 366
David C. Kressin United States 6 141 0.5× 144 1.2× 119 1.3× 69 0.9× 23 0.5× 8 420
Sathish Parasuraman United Kingdom 8 144 0.5× 27 0.2× 147 1.5× 51 0.7× 21 0.4× 16 285
Vivek Kumar India 11 110 0.4× 23 0.2× 29 0.3× 29 0.4× 30 0.6× 23 400
Y. Schwartz Israel 10 44 0.2× 37 0.3× 88 0.9× 64 0.8× 38 0.8× 29 314
Milena Cecere Italy 10 205 0.7× 23 0.2× 385 4.1× 58 0.8× 22 0.4× 15 509
Masatomo Yashiro Japan 12 99 0.3× 42 0.3× 53 0.6× 92 1.2× 76 1.6× 38 447
Daisuke Kanda Japan 12 39 0.1× 48 0.4× 80 0.8× 101 1.3× 69 1.4× 55 371

Countries citing papers authored by H. James Ford

Since Specialization
Citations

This map shows the geographic impact of H. James Ford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. James Ford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. James Ford more than expected).

Fields of papers citing papers by H. James Ford

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. James Ford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. James Ford. The network helps show where H. James Ford may publish in the future.

Co-authorship network of co-authors of H. James Ford

This figure shows the co-authorship network connecting the top 25 collaborators of H. James Ford. A scholar is included among the top collaborators of H. James Ford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. James Ford. H. James Ford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ataya, Ali, et al.. (2024). REAL-WORLD ORAL TREPROSTINIL INITIATIONS: INSIGHTS FROM SPECIALTY PHARMACY DATA. CHEST Journal. 166(4). A5824–A5826.
2.
Ford, H. James, et al.. (2024). Exploring the patient perspective in pulmonary hypertension. European Respiratory Journal. 64(4). 2401129–2401129. 3 indexed citations
3.
Al‐Qadi, Mazen O., et al.. (2023). Prognostic Value of Respiratory Variation in Right Atrial Pressure in Patients With Precapillary Pulmonary Hypertension. CHEST Journal. 164(2). 481–489. 5 indexed citations
4.
Al‐Qadi, Mazen O., et al.. (2021). Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension. Frontiers in Medicine. 7. 616720–616720. 11 indexed citations
5.
Ford, H. James, Wayne H. Anderson, Blair Wendlandt, et al.. (2020). Randomized, Placebo-controlled Trial of Inhaled Treprostinil for Patients at Risk for Acute Respiratory Distress Syndrome. Annals of the American Thoracic Society. 18(4). 641–647. 8 indexed citations
6.
Preston, Ioana R., Charles D. Burger, Sonja Bartolome, et al.. (2020). Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial. The Journal of Heart and Lung Transplantation. 39(5). 464–472. 27 indexed citations
7.
Fares, Wassim H., George A. Stouffer, Robert M. Aris, et al.. (2020). Thermodilution and Fick Cardiac Outputs Differ: Impact on Pulmonary Hypertension Evaluation. UNC Libraries. 1 indexed citations
8.
Badesch, David B., Todd M. Bull, Murali M. Chakinala, et al.. (2020). EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. European Respiratory Journal. 57(2). 2000414–2000414. 26 indexed citations
9.
10.
Ford, H. James, Wayne H. Anderson, Thomas Bice, et al.. (2019). INHALED TREPROSTINIL FOR PATIENTS AT RISK FOR ARDS. CHEST Journal. 156(4). A992–A993. 1 indexed citations
11.
Pathak, Vikas, et al.. (2018). Effect of 6-min Walk Test on pro-BNP Levels in Patients with Pulmonary Arterial Hypertension. Lung. 196(3). 315–319. 8 indexed citations
12.
Lee, David W., et al.. (2018). The Value of Bedside Echocardiogram in the Setting of Acute and Chronic Pulmonary Embolism. Clinics in Chest Medicine. 39(3). 549–560. 3 indexed citations
13.
Ford, H. James, Robert P. Baughman, R M Aris, Pedro Engel Gonzalez, & James F. Donohue. (2016). Tadalafil Therapy for Sarcoidosis‐Associated Pulmonary Hypertension. Pulmonary Circulation. 6(4). 557–562. 30 indexed citations
14.
Fares, Wassim H., H. James Ford, Andrew J. Ghio, & Robert M. Aris. (2012). Safety and Feasibility of Obtaining Wedged Pulmonary Artery Samples and Differential Distribution of Biomarkers in Pulmonary Hypertension. Pulmonary Circulation. 2(4). 477–482. 6 indexed citations
15.
Fares, Wassim H., George A. Stouffer, Patricia P. Chang, et al.. (2012). Thermodilution and Fick Cardiac Outputs Differ: Impact on Pulmonary Hypertension Evaluation. Canadian Respiratory Journal. 19(4). 261–266. 40 indexed citations
16.
Judson, Marc A., Kristin B. Highland, Soon-Ho Kwon, et al.. (2011). Ambrisentan for sarcoidosis associated pulmonary hypertension.. PubMed. 28(2). 139–45. 76 indexed citations
17.
Fares, Wassim H., H. James Ford, & Robert M. Aris. (2011). Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment,and Dana Point World Symposium Highlights. Current Respiratory Medicine Reviews. 7(4). 279–288. 1 indexed citations
18.
Ford, H. James & Robert Roubey. (2010). Pulmonary Manifestations of the Antiphospholipid Antibody Syndrome. Clinics in Chest Medicine. 31(3). 537–545. 20 indexed citations
19.
Judson, Marc A., et al.. (2010). Ambrisentan For Sarcoidosis Associated Pulmonary Hypertension (SAPH). A2368–A2368. 3 indexed citations
20.
Wheless, Stephen A., Margaret L. Gulley, Nancy Raab‐Traub, et al.. (2008). Post-transplantation Lymphoproliferative Disease. American Journal of Respiratory and Critical Care Medicine. 178(10). 1060–1065. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takayuki Jujo Breakdown of academic impact, for papers by Koichiro Fukuda Breakdown of academic impact, for papers by Jerzy Piecuch Breakdown of academic impact, for papers by David C. Kressin Breakdown of academic impact, for papers by Sathish Parasuraman Breakdown of academic impact, for papers by Vivek Kumar Breakdown of academic impact, for papers by Y. Schwartz Breakdown of academic impact, for papers by Milena Cecere Breakdown of academic impact, for papers by Masatomo Yashiro Breakdown of academic impact, for papers by Daisuke Kanda
Rankless by CCL
2026